Clinical Trial Search

Primary: Part A: Number of Participants With Dose-limiting Toxicities (DLTs) — 0; 0 Participants

Primary: Incidence of Adverse Events — 5; 5; 5; 3 participants

Primary: Overall Response Rate — 11.1 probability

Primary: Identify Cancer Patients Who Meet Criteria for Genetic Counseling and Testing — 100; 48 patients

Primary: Percentage of Daily Workbook Entries Completed — 44 percent

Primary: Percentage of MSM Index Cases That Respond to the Follow-up Survey at 3 Months After Enrollment — 92.6; 82.5 percentage of participants

Primary: Change From Baseline to Week-26 in Alzheimer's Disease Assessment Scale-Cognitive Subscale 11 (ADAS-Cog 11) — 2.0; 2.5; 2.6 score on a scale — p=0.41

Primary: Diurnal Level 2 Hypoglycemia Events (ADA, <54 mg/dL) as Measured by CGM in Patients With Severe Hyperinsulinemic Hypoglycemia (HH) — 5.2; 5.2; 2.7; 2.1 events per 14…

Primary: Objective Response Rate (ORR) by Investigator — 4.3; 5.0; 13.2; 0 Percent of participants

Primary: Patient Experienced Any Grade 3-5 Toxicity — 0.51; 0.71 proportion of participants — p=0.0001

Primary: Fundus Autofluorescence Imaging to Measure the Rate of Change in Area of Geographic Atrophy — 0.41; 0.35 mm/year — p=0.39

Primary: Graft-Versus-Host Disease-Free, Relapse-Free Survival (GRFS) at 1 Year — 53; 84 percentage of survival probability

Primary: Percentage of Participants With Solicited Local Adverse Events (AEs) Post First Vaccination — 70.9; 78.2; 27.3 percentage of participants

Primary: Percent of Patients Who Are Progression Free at 2 Years — 45.0; 36.4 percentage of participants

Primary: Change From Baseline in Hypoparathyroidism Symptom Diary (HypoPT-SD) Symptom Subscale Score at Week 26 — -0.93; -1.46 score on a scale — p==0.003